Intrexon Corp., of Germantown, Md., said it closed its public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 731,707 shares of common stock at $41 per share. Read More
Nantkwest Inc., of Los Angeles, along with teams at the University of Michigan and Thomas Jefferson University, disclosed a $1 million challenge award from the Prostate Cancer Foundation to study the company's natural killer (NK) cell-based therapy in advanced prostate cancer. Read More
Oncolytics Biotech Inc., of Calgary, Alberta, completed enrollment of 166 patients in a randomized phase II study of the reovirus variant Reolysin in patients with previously treated advanced or metastatic non-small-cell lung cancer. Read More
The National Institute of Allergy and Infectious Diseases launched a study that will expose healthy adults to respiratory syncytial virus (RSV) to shed more light on how RSV infections develop and the immune system responds. Read More
In his 35 years at Pfizer Inc., including tenure as the New York-based pharma's director of R&D operations, Frank Sciavolino was immersed in the science side of the business and didn't necessarily see himself in the role of a CEO. Despite his role as the co-founder and head of Thetis Pharmaceuticals LLC, Sciavolino opted for the title of chief scientific officer. Read More
On the eve of the next round of user fee negotiations, MDUFA and PDUFA received scathing grades for their unintended consequences and negative impact on drug and device innovation. Read More
Merus BV, a Dutch developer of bispecific antibodies for cancer immunotherapy, claimed the first tranche of a €72.8 million (US$80.5 million) series financing led by Sofinnova Ventures and Novo A/S, with additional backing from RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management, an unnamed U.S. investor and earlier supporters. Read More
LONDON – The rush into T-cell immunotherapy continues, with Germany's Immatics Biotechnologies GmbH teaming up with MD Anderson Cancer Center in the formation of a $60 million U.S. subsidiary. Read More
